Identification of hemoglobin-α and -β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer
Identification of hemoglobin-α and -β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer
复制标题
DOI：
10.1111/j.1349-7006.2005.00029.x
复制
发表时间：
2005-03-01
期刊：
影响因子：
5.7
通讯作者：
Jin, HS
中科院分区：
文献类型：
--
作者：
Ahn, WS;Park, SP;Jin, HS
开发新的卵巢癌生物标志物对于改善卵巢癌的检测和监测显然是必要的。表面增强激光解吸电离飞行时间质谱法（SELDI-TOF-MS）可用于鉴别癌细胞中差异表达蛋白。因此，本研究的目的是确定卵巢癌的潜在诊断血清学生物标志物。采用SELDI蛋白芯片阵列对45份血清样本进行蛋白表达差异分析。从卵巢癌患者（n = 35）和正常健康女性（n = 10）抽取45份血清，在SELDI蛋白芯片表面进行分析。用CM-Sepharose纯化候选生物标志物，测定其n端氨基酸序列。采用酶联免疫吸附试验（ELISA）测定肿瘤患者血清中血红蛋白（Hb）与正常人血清的含量。使用WCX2阵列筛选卵巢癌患者与正常健康女性血清中表达差异显著（P < 0.05）的9个血清蛋白。在卵巢癌样品中检测到的最明显的多肽峰位于15.1和15.8 kDa处，这两个峰分别被鉴定为血红蛋白- α (hb - α)和- β (hb - β)链。ELISA结果显示，与正常健康女性血清相比，卵巢癌患者血清对完整Hb水平的敏感性为77%。总之，我们发现了两种卵巢癌生物标志物蛋白，分别为hb - α和hb - β。通过ELISA检测，卵巢癌血清样本与正常健康女性血清样本的Hb水平有显著差异。需要进一步的研究来进一步验证hb - α和hb - β生物标志物。
The development of new biomarkers for ovarian cancer is clearly necessary for the improved detection and monitoring of the disease. Surface enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) can be employed in the identification of differentially expressed proteins in cancer cells. The objective of this study was, then, to identify potential diagnostic serological biomarkers for ovarian cancer. We performed protein expression difference analyses of 45 serum samples using SELDI protein chip array. Forty-five sera obtained from ovarian cancer patients (n = 35) and normal healthy females (n = 10),were profiled on the surface of SELDI protein chip. The candidate biomarkers were purified by CM-Sepharose, and their N-terminal amino sequence was determined. The amounts of hemoglobin (Hb) in cancer patient's sera versus that of normal sera were measured by ELISA. Nine sera proteins that were found to be significantly differentially expressed (P < 0.05) between the sera of ovarian cancer patients and that of normal healthy females were selected using the WCX2 array. The most distinctive polypeptide peaks detected in the ovarian cancer samples were at 15.1 and 15.8 kDa and these two peaks were identified as the hemoglobin-alpha (Hb-alpha) and -beta (Hb-beta) chain, respectively. ELISA indicated that the sensitivity for intact Hb level was 77% in sera obtained from ovarian cancer patients, as compared with normal healthy female sera. In conclusion, two ovarian cancer biomarker proteins were discovered and identified as Hb-alpha and Hb-beta. Hb levels were significantly different in ovarian cancer serum samples and those obtained from normal healthy females, as determined by ELISA. Additional studies are required to further validate Hb-alpha and Hb-beta biomarkers.